Subscribe To

Price Alert Latest News Economic Calendar News

OPK / OPKO Health's Future After Merck Deal: Bright Or Uncertain

In the first three months of 2023, the company posted $237.6 million in revenue, up 28.2% from the previous quarter. In addition to the Merck deal, OPKO received a $7 million payment from Vifor in Q1 2023, thanks to the German price approval for Rayaldee. Read More

Demo Live Account See Partner Details

Content Topics

Opko

Health

Future

After

Merck

Deal

Bright

Uncertain

Health s

Stock

OPK

Posted: May 11 2023, 12:29

Author Name: Seeking Alpha

OPK News

By GlobeNewsWire
October 31, 2023

OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023

MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months

By GlobeNewsWire
October 25, 2023

OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023

MIAMI, Oct. 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical data on RAYALDEE® extended-release calci

By Zacks Investment Research
October 6, 2023

OPKO Health (OPK) Gets BARDA Contract to Combat Antibody Threats

OPKO Health's (OPK) latest awarded funding is likely to enable the development of novel multispecific antibodies against viral infectious disease thre

By Zacks Investment Research
September 13, 2023

OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations

OPKO Health's (OPK) latest Research Collaboration Agreement is likely to enable it to expand its pipeline to develop orally administered tablet presen

By Zacks Investment Research
August 28, 2023

Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio

OPKO Health's (OPK) potential in RAYALDEE raises optimism about the stock.

By Zacks Investment Research
August 7, 2023

OPKO Health (OPK) Q2 Earnings and Revenues Top Estimates

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall second-quarter results reflect soft perform

By Seeking Alpha
August 4, 2023

OPKO Health, Inc. (OPK) Q2 2023 Earnings Call Transcript

OPKO Health, Inc. (NASDAQ:OPK ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations

By Zacks Investment Research
August 3, 2023

OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates

OPKO Health (OPK) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.